decisionhealth Newsletters, Part B News - 2004 Issue 9 (September)
Limit your losses from unlisted drug code denials
Subscribe or sign in to view the full article.
Article Overview
This article discusses reimbursement challenges associated with unlisted drug billing and the operational steps practices may take to reduce denials or underpayment. It focuses on Medicare and carrier payment behavior, local coverage information, documentation expectations, and administrative strategies relevant to coding and billing staff working with drugs that do not yet have assigned codes.
Why This Topic Matters
Unlisted drug claims can be difficult to price, may be denied or paid below acquisition cost, and often require careful documentation and payer follow-up. The article is relevant to practices that bill drugs under unlisted HCPCS codes and need to understand how carrier policies, reference pricing, and claim support affect payment.
What You Will Learn
- How unlisted drug claims are treated by payers in general
- Why reimbursement for drugs without established codes can vary
- What types of documentation are commonly associated with unlisted drug claims
- How carrier and Medicare pricing references may affect payment
- General administrative approaches practices use when facing denials or low payments
Who Should Read This
- Medical coders
- Billing staff
- Practice managers
- Revenue cycle personnel
- Physician office administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com